Floatz logo

VEMURAFENIB

Melanoma, Malignant, of Soft Parts

Radboud University Medical CenterSmall moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Melanoma, Malignant, of Soft Parts cohort.

Asset / SponsorPhaseRating
Tivantinib
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2B
Crizotinib
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2B
Cobimetinib
Radboud University Medical Center
Phase 2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC

View all 19 →

Same molecule, other indications

VEMURAFENIB is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
metastatic melanomaDormant
B
Indicative ·
63 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →